Story
Xinjiyuan Pharma Refiles for Hong Kong IPO Amidst Severe Cash Shortage

Guangzhou Xinjiyuan Pharmaceutical Co., Ltd., a clinical-stage company specializing in novel drug delivery systems, has refiled its application for a mainboard listing on the Hong Kong Stock Exchange. The move comes just two months after its previous application lapsed and highlights the firm's urgent need for capital, with its prospectus indicating existing cash reserves can only sustain operations for approximately eight months.
Financial Pressure Mounts
According to its filing, Xinjiyuan Pharma is facing significant financial strain. The company has not yet commercialized any of its core products, generating revenue primarily from CRO services and a single licensed product sold in the U.S. For the fiscal years 2024 and 2025, and the first five months of 2026, the company reported accumulating net losses.
- Accumulated Losses: The company recorded a total net loss of RMB 455.2 million over the reporting period.
- Cash Position: As of May 31, 2026, cash and cash equivalents stood at approximately RMB 103 million.
- Liabilities: The firm reported net current liabilities of RMB 573 million and total net liabilities of RMB 533 million.
Despite raising a total of RMB 291 million through six funding rounds, the company's cash burn from research and development and administrative costs is substantial. Its last funding round in November 2025 gave it an implied valuation of RMB 1.53 billion, a figure the upcoming IPO will test amid the firm's precarious financial health.
A Bet on Novel Drug Delivery
Unlike traditional pharmaceutical companies focused on new molecule discovery, Xinjiyuan's strategy centers on improving existing, approved drugs through advanced delivery technologies. The company is developing products based on two core platforms: a soluble microneedle system for painless transdermal administration and a nasal inhalation platform for rapid drug delivery to the central nervous system.
AdThis approach aims to address limitations of conventional drug formulations, such as invasive injections or poor patient compliance, by creating value-added medicines with improved therapeutic profiles. However, the success of this strategy hinges on proving the clinical efficacy and safety of its pipeline candidates.
Pipeline Progress and Hurdles
Xinjiyuan's two lead assets are in mid-stage clinical development, but crucial efficacy data has not yet been disclosed, a key risk highlighted in its filing.
- DHMP Microneedle Patch: A dexmedetomidine patch for pre-operative sedation. It is the first soluble microneedle drug patch to receive clinical trial approval in China. A Phase IIa trial for pediatric use was completed in June 2026, and a Phase II trial for adults began in March 2026.
- XJN010 Nasal Spray: A formulation for the on-demand treatment of "OFF" episodes in Parkinson's disease patients. A Phase II trial in China was completed in April 2026, and the product has received IND approval in the U.S. to proceed directly to Phase II trials.
While these products target markets with significant unmet needs, the company faces substantial technical and regulatory challenges. These include scaling up manufacturing for its microneedle technology, ensuring stability and sterility, and navigating a regulatory landscape that currently lacks specific guidelines for such novel products. The prospectus acknowledges that the clinical benefit of its candidates remains unproven.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.